Watch NEPH. Know when insiders buy.
One email the day a filing lands. Free.
NEPH
NEPHROS INC
4.29
−0.09 −2.05%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
73
PASS · shorts 73
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $46.6MP/E 26.8DIV YIELD —FCF YIELD —REV TTM $20.7M +24.2%NET INCOME $1.7M +30.8%NET CASH $4.6M52W 2.78 – 5.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $6M | +36.2% | 66.9% | $1.2M | $1.2M | +405.1% | 0.11 | $681K | — | — | Aug 10 |
| Q1 2026 · Mar 31 | $5.2M | +6.9% | 57.4% | $97K | $140K | −74.9% | 0.01 | −$1.7M | — | — | Aug 10 |
| Q4 2025 · Dec 31derived | $4.7M | +22.2% | 58.4% | $18K | $62K | −82.2% | 0.01 | $185K | — | — | Aug 10 |
| Q3 2025 · Sep 30 | $4.8M | +35.4% | 61.2% | $314K | $337K | +84.2% | 0.03 | $99K | — | — | Nov 6 |
| Q2 2025 · Jun 30 | $4.4M | +35.9% | 63.2% | $248K | $237K | — | 0.02 | $994K | — | — | Aug 10 |
| Q1 2025 · Mar 31 | $4.9M | +38.5% | 64.7% | $566K | $558K | — | 0.05 | $322K | — | — | Aug 10 |
| Q4 2024 · Dec 31derived | $3.9M | +18.9% | 64.0% | $317K | $349K | — | 0.04 | $1.3M | $0 | $1.3M | Mar 12 |
| Q3 2024 · Sep 30 | $3.5M | −6.0% | 61.1% | $206K | $183K | — | 0.02 | −$623K | $0 | −$623K | Nov 6 |
| Q2 2024 · Jun 30 | $3.3M | — | 58.8% | −$317K | −$289K | — | -0.03 | −$501K | — | — | Nov 6 |
| Q1 2024 · Mar 31 | $3.5M | — | 62.1% | −$200K | −$169K | — | -0.02 | −$672K | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | $3.3M | — | 62.1% | −$649K | −$654K | — | -0.06 | −$237K | — | — | Mar 24 |
| Q3 2023 · Sep 30 | $3.7M | — | 58.6% | −$203K | −$182K | — | -0.02 | $562K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $18.8M | 61.9% | $1.1M | $1.2M | 6.4% | 0.11 | $1.6M | — | — | — | — |
| FY2024 · to Dec 31 | $14.2M | 61.6% | $6K | $74K | 0.5% | 0.01 | −$492K | $55K | −$547K | — | — |
| FY2023 · to Dec 31 | $14.2M | 59.0% | −$1.6M | −$1.6M | -11.1% | -0.15 | $827K | $75K | $752K | — | — |
| FY2022 · to Dec 31 | $10M | 47.4% | −$4.3M | −$7.1M | -71.2% | -0.73 | −$3.2M | $137K | −$3.4M | — | — |
| FY2021 · to Dec 31 | $10.2M | 55.1% | −$3.3M | −$3.9M | -37.8% | -0.41 | −$1.4M | $36K | −$1.5M | — | — |
| FY2020 · to Dec 31 | $8.6M | 57.4% | −$4.3M | −$4.5M | -52.9% | -0.52 | −$6.9M | $239K | −$7.1M | — | — |
Every number comes from NEPHROS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.